Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2596068 | 0.87 | OPRK1 (0.42) | ALDH1A1SMN1; SMN2OPRK1GAA | |
| SCHEMBL2592735 | 0.82 | PRPS1 (0.39) | OPRK1MAPT | |
| SCHEMBL2592646 | 0.81 | KDM4E (0.41) | ALDH1A1LMNAOPRK1KDM4ERXFP1 | |
| SCHEMBL2588328 | 0.76 | PIK3CD (0.39) | ALDH1A1LMNAKDM4ERXFP1GAA | |
| SCHEMBL19621047 | 0.76 | LMNA (0.44) | ALDH1A1LMNASMN1; SMN2KDM4ENPSR1 | |
| SCHEMBL7131487 | 0.76 | LMNA (0.55) | ALDH1A1MAPK1LMNASMN1; SMN2OPRK1 | |
| SCHEMBL7512469 | 0.74 | LMNA (0.58) | ALDH1A1LMNASMN1; SMN2OPRK1KDM4E | |
| SCHEMBL29576838 | 0.74 | LMNA (0.58) | ALDH1A1LMNASMN1; SMN2OPRK1KDM4E | |
| SCHEMBL308369 | 0.73 | CA12 (0.48) | ALDH1A1MAPK1NPSR1 | |
| SCHEMBL308549 | 0.71 | GLA (0.41) | ALDH1A1MAPK1NPSR1GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| US-9446041-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| EP-2773754-B1 | Compounds for use in the treatment of T-cell mediated diseases | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-08-03 | — | — | EP | disclosed |
| US-9402836-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160074394-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2016-03-17 | — | — | US | disclosed |
| US-9242962-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20150313887-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2015-11-05 | — | — | US | disclosed |
| US-9114141-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150141436-A1 | INDOLES | KIDS2, INC. | 2015-05-21 | — | — | US | disclosed |
| US-8975291-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140256739-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2014-09-11 | — | — | US | disclosed |
| EP-2773754-A1 | METHOD OF TREATMENT | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-09-10 | — | — | EP | disclosed |
| US-20130345200-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2013-12-26 | — | — | US | disclosed |
| US-8536179-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2013067296-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| EP-2566327-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074394-A1 | METHOD OF TREATMENT | EZH1, EZH2, SUV39H2 | ALDH1A1 1584/4885MAPK1 1293/4885LMNA 4613/4885 |
| US-20150141436-A1 | INDOLES | IDO1, IDO2, INMT | ALDH1A1 38/4885MAPK1 3896/4885LMNA 3727/4885 |
| US-20140256739-A1 | METHOD OF TREATMENT | EZH1, EZH2, SUV39H2 | ALDH1A1 1584/4885MAPK1 1293/4885LMNA 4613/4885 |
| US-20150313887-A1 | INDOLES | IDO1, IDO2, INMT | ALDH1A1 38/4885MAPK1 3896/4885LMNA 3727/4885 |
| US-20130345200-A1 | INDOLES | IDO1, IDO2, INMT | ALDH1A1 38/4885MAPK1 3896/4885LMNA 3727/4885 |
| US-20130053397-A1 | INDOLES | IDO1, IDO2, INMT | ALDH1A1 45/4885MAPK1 3975/4885LMNA 3700/4885 |
| US-20160296518-A1 | INDOLES | IDO1, IDO2, INMT | ALDH1A1 38/4885MAPK1 3896/4885LMNA 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.